Simcere Pharma Innovation Revenue Hits 85% as President Admits Slow Transformation
Simcere Pharmaceutical Group reported first-half 2026 revenue of 4.58 billion yuan, up 27.8% year-on-year, with innovative drug revenue accounting for 84.9% of total revenue. President Zhou Yunshu acknowledged the company was too slow in pivoting from generics to innovation. Simcere has invested over 9 billion yuan in R&D during the 14th Five-Year Plan period, built a pipeline of over 90 projects, and completed out-licensing deals worth over $6.1 billion. The company now targets over 10 billion yuan in full-year revenue and plans to double R&D spending to over 18 billion yuan in the 15th Five-Year Plan period.
IllustrationEditorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page reads the event directly, while its address stays stable when the title changes.
- Summary covers the current reports
Cross-source coverage
Reporting timeline
Simcere's Innovation Transformation: Lessons from a Latecomer Racing to Catch Up in China's Pharma Sector
Simcere Pharmaceutical Group, a traditional Chinese generic drugmaker founded in 1995, has undergone a strategic transformation toward innovative drugs over the past decade. In the first half of 2026, the company reported total revenue of 4.58 billion yuan, up 27.8% year-on-year, with innovative drug revenue accounting for 84.9% of total revenue. The company has raised its full-year revenue target to over 10 billion yuan. President Zhou Yunshu candidly admitted the company's biggest lesson was being too slow and lacking firm resolve in its innovation pivot, despite starting early. Simcere has invested over 9 billion yuan in R&D during the 14th Five-Year Plan period, expanding its R&D team to 1,000. The company now has 11 innovative drug products and a pipeline of over 90 projects. It is pursuing internationalization through licensing deals, including partnerships with Boehringer Ingelheim and Roche, with total potential deal value exceeding $6.1 billion. Zhou outlined a strategy for 'Innovation 2.0' focused on global innovation, aiming for drug approvals in Western markets, with R&D spending projected to exceed 18 billion yuan during the 15th Five-Year Plan period. The article positions Simcere's journey as a case study for traditional Chinese pharma companies navigating the transition from generics to innovation amid supportive government policies.
Read sourceSimcere President Zhou Yunshu Says Innovation Not Fast Enough, Aims for BD as Second Growth Curve
In a media briefing on September 19, Simcere Pharmaceutical Group President Zhou Yunshu acknowledged that the company's biggest lesson from its innovation transformation is that it was not fast or decisive enough, citing a lingering dual focus on generics and innovative drugs that caused missed opportunities. He emphasized that business development (BD) will serve as the company's 'second growth curve' to fill pipeline gaps. Simcere's 2026 first-half innovative drug revenue reached 3.89 billion yuan, up 34.1% year-on-year, accounting for 84.9% of total revenue. Zhou outlined an optimized overseas BD strategy, moving away from a single out-licensing model toward a multi-dimensional evaluation system, including priority self-development for globally competitive assets and New-Co structures. He expressed confidence that multinational drugmakers will continue buying Chinese innovative assets, noting their patent cliffs and increased BD hiring in China, but warned that homogeneous pipelines, such as the over 20 domestic RAS-targeting projects, are a supply-side risk. Simcere aims for 10 billion yuan in 2026 revenue.
Read sourceSimcere Pharma's Transformation: From Generics to Innovation, Catching Up in China's Drug Race
Simcere Pharmaceutical Group, a Chinese drugmaker founded in 1995 on generics, has undergone a strategic transformation toward innovative drugs. In the first half of 2026, the company reported total revenue of 45.8 billion yuan (up 27.8% year-on-year), with innovative drug revenue reaching 38.87 billion yuan, accounting for 84.9% of total revenue. Adjusted net profit rose 48.7% to 9.64 billion yuan. The company has raised its full-year revenue target to over 100 billion yuan and profit target to 18 billion yuan. President Zhou Yunshu acknowledged the company was 'late' in fully committing to innovation, citing a period of indecision between generics and innovative drugs. Simcere has since increased R&D spending from under 20 billion yuan in the 13th Five-Year Plan period to over 90 billion yuan in the 14th, and expanded its R&D team from 300 to 1,000. The company now has 11 innovative drug products and a pipeline of over 90 projects. It has also accelerated out-licensing deals, including a potential 10.58 billion euro deal with Boehringer Ingelheim and a 14.55 billion dollar deal with Roche. Zhou outlined a strategy for 'Innovation 2.0' focused on global markets, with plans to double R&D spending to over 180 billion yuan in the 15th Five-Year Plan period and pursue overseas clinical development and commercialization.
Read sourceShow 2 older updatesHide older updates
Simcere Pharma's 'Late Start' and 'Catching Up': Innovation Revenue Hits 85% as Firm Targets $100B Annual Sales
Simcere Pharmaceutical Group reported strong first-half 2026 results: total revenue of 45.8 billion yuan (up 27.8% YoY), adjusted net profit of 964 million yuan (up 48.7%), and innovative drug revenue reaching 84.9% of total sales. The company has raised its full-year revenue target to over 100 billion yuan and profit target to 18 billion yuan. President Zhou Yunshu candidly acknowledged the company's slow initial transformation from generics to innovation, calling it a 'lesson.' Simcere has invested over 90 billion yuan in R&D during the 14th Five-Year Plan period, built a pipeline of 90+ innovative drug candidates, and completed six out-licensing deals worth over $6.1 billion in total potential value. Key products include the stroke drug Xianbixin (cumulative sales over 100 billion yuan) and insomnia drug Daridorexant. The company is now pursuing 'Innovation 2.0' with a focus on global markets, planning to double R&D spending to 180 billion yuan in the 15th Five-Year Plan period and exploring overseas independent development and co-development models. Zhou predicted Chinese pharma companies will further differentiate into global leaders and specialized biotechs.
Simcere Pharmaceutical's Strategic Transformation: From Generics to Innovation and Global Ambitions
This article from 21st Century Business Herald analyzes Simcere Pharmaceutical Group's transformation from a generic drug maker to an innovation-driven biopharma company. In the first half of 2026, Simcere reported total revenue of 45.8 billion yuan (up 27.8% year-on-year), with innovative drug revenue accounting for 84.9% of total revenue. The company raised its full-year revenue target to over 100 billion yuan and profit target to 18 billion yuan. President Zhou Yunshu candidly acknowledged the company's past mistakes, including slow transformation speed and lack of firm goals. The article details Simcere's R&D investments (over 90 billion yuan during the 14th Five-Year Plan period), its pipeline of 11 innovative drugs, and its business development strategy shift from early-stage licensing ('selling seedlings') to deeper partnerships and global co-development. Simcere has completed six out-licensing deals worth over $6.1 billion. The company is now pursuing 'Innovation 2.0' with a focus on global markets, planning to spend over 180 billion yuan on R&D during the 15th Five-Year Plan period. The article places Simcere's story in the context of China's 15th Five-Year Plan for pharmaceutical development, which aims to make biopharma a strategic pillar industry.
Read source